On Thursday, ARS Pharmaceuticals received an upgrade to its Relative Strength (RS) Rating, from 68 to 76.
IBD's proprietary rating identifies share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves. See if ARS Pharmaceuticals can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
ARS Pharmaceuticals is not currently near a potential buy zone. See if the stock goes on to build a base that could launch a new move.
ARS Pharmaceuticals reported 0% earnings growth in its most recent report, while sales growth came in at 4,900%. Look for the next report on or around Mar. 20.
ARS Pharmaceuticals earns the No. 204 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics, Catalyst Pharmaceuticals and United Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
